Recombinant Human gp130/IL6ST protein (His Tag)

Species

Human

Purity

>95 %, SDS-PAGE

Tag

His Tag

Activity

EC50: 90-370 ng/mL

Cat no : Eg0654



Product Information

Purity >95 %, SDS-PAGE
Endotoxin <0.1 EU/μg protein, LAL method
Activity
Immobilized Human gp130 (His tag) at 1 μg/mL (100 μL/well) can bind Human IL-6R alpha (Myc tag, His tag) with a linear range of 90-370 ng/mL.
Expression HEK293-derived Human gp130 protein Glu23-Ile618 (Accession# P40189-1) with a His tag at the C-terminus.
GeneID 3572
Accession P40189-1
PredictedSize 68.5 kDa
SDS-PAGE 80-100 kDa, reducing (R) conditions
Formulation Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage Conditions
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

Glycoprotein 130 (gp130, also known as IL6ST, CD130 or IL6-beta) is a ubiquitously expressed, signal-transducing receptor that serves as the signal transduction unit for IL-6 family of cytokines, including IL-6, IL-11, IL-27, leukemia inhibitory factor (LIF), OSM, ciliary neurotrophic factor (CNTF), cardiotrophin 1 (CT-1), and cardiotrophin-like cytokine (CLC). These cytokines signal through the gp130/Jak/STAT pathway. Binding of IL-6 to IL-6R induces gp130 homodimerization and formation of a high-affinity receptor complex, which activates Jaks. That causes phosphorylation of gp130 tyrosine residues which in turn activates STAT3. gp130 is a type I transmembrane protein, and can also exist as a soluble form (sgp130). sgp130 binds to sIL-6R/IL-6 complexes and prevents their interactions with membrane-anchored gp130 on target cells.

References:

1. Taga T, Kishimoto T. (1997). Annu Rev Immunol. 15:797-819. 2. Montero-Julian FA, et al. (1997). Clin Cancer Res. 3(8):1443-1451. 3. Heinrich PC, et al. (1998). Biochem J. 334 (Pt 2)(Pt 2):297-314. 4. Silver JS, Hunter CA. (2010). J Leukoc Biol. 88(6):1145-1156.